Jun 21, 2023, 18:41
So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC
In a post by Arun Azad on Twitter, it says, “So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC. Impressive rPFS & OS data in this population (see Table). A big win for a lot of pts as approx. 25% of 1L mCRPC pts are HRR-deficient.”
Source: Arun Azad/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 5, 2024, 00:57
Dec 5, 2024, 00:45
Dec 5, 2024, 00:30
Dec 5, 2024, 00:09
Dec 4, 2024, 23:08